Über uns
Dürfen wir uns vorstellen?
Incyte is a growing Global Biotech/ Oncology Company with a focus in targeted / immuno therapy with a strong pipeline which addresses 11 key molecular targets in interdependent oncogenic pathways.
Incyte was placed at the 4th innovative company in the world of all industries by the Forbes magazine in 2016.
Incyte is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, primarily for oncology. Our vision is to become a leader in the development and delivery of novel drugs for serious unmet medical needs.
We have established multiple collaborations with major pharmaceutical companies to support the clinical development and global commercialization of several of our compounds.
The Incyte corporate headquarters is located in Wilmington, Delaware, and more than 625 employees comprise our experienced management, discovery, clinical development and commercial teams. Our assets, experience and prior success in bringing important new drugs to market put us in a strong position to make a difference by improving the lives of patients and buildings sustainable value for our shareholders.
